A selection of recent successful placements and new projects globally. Focus in the 4th quarter of 2020 has been mainly on Rare diseases, Artificial Intelligence, Dental, Vaccines, P.O.C. Diagnostics, Gene therapy, Oncology, Cardiovascular, Women’s health, Neurology, Animal health and Venture teams.
Author: Alison James
Coulter Partners was delighted to partner with ObsEva SA (NASDAQ: OBSV / SIX: OBSN) to secure the appointment of Brian O’Callaghan as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will succeed Dr Ernest Loumaye and be proposed for election on ObsEva’s Board of Directors at the next company AGM. ObsEva SA is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health
Global Life Sciences search specialist, Coulter Partners and BioInnovation Institute (BII), the international incubator in Denmark for research-based innovation and entrepreneurship, are delighted to announce a ground-breaking collaboration agreement. Coulter Partners has been engaged to provide support for BII across three workstreams; providing assessment, coaching and development for the CEOs of start-up businesses in BII’s portfolio under the Creation House Programme, hiring chairs and board directors to support these businesses and conducting executive search for their portfolio companies where needed.
Coulter Partners recently talked to Dr Cornelius Maas, Senior Investment Manager at SHS Capital about leadership hiring and Betterguards, a SHS portfolio company. Betterguards is pioneering smart technology to prevent joint injuries and Coulter Partners helped secure the appointment of their new CEO, Jocelyn Robiot.
The intensity of talent demand in the Life Sciences sector has fuelled continued growth at global executive search specialist, Coulter Partners and we are delighted to announce a number of key hires in 2020. Marianne McNamara, SHRM-SCP has joined as Operations Director for the US, while Evan Fishel is appointed Director on the West Coast and Mike Miano, Senior Associate in New Jersey. In London the team is strengthened with Ben Hobbins as Senior Consultant and Hafsah Bhatti as Associate, while research capacity is also expanded across the team.
The Surge in Cell and Gene Therapies The Cell and Gene Therapy (CGT) sector is booming. Despite their scientific and clinical complexities, numerous advanced biological products are bringing notable treatment efficacy across multiple therapeutic areas based on their ability to deliver precision medicine. The Food and Drug Administration (FDA) predicts that by 2025 it will Read More …
Coulter Partners was very pleased to partner once again with Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, to secure the appointment of Jason A. Amello as Chief Financial Officer. Jason will be based in the U.S. and will support Saniona’s advancement of late-stage clinical trials with lead product candidate Tesomet in two rare eating disorders, hypothalamic obesity (HO) and Prader Willi Syndrome (PWS).
Coulter Partners was very pleased to partner recently with Sequana Medical NV, an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, to secure the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer.
Coulter Partners was delighted to partner recently with Optimapharm to secure the appointment of Dr. Andrew Copestake as Chief Executive Officer. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors. Optimapharm is a contract research organization managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe.
Coulter Partners recently talked to Tanja Dowe, Chief Executive Officer of Debiopharm Innovation Fund S.A. about digital disruption and talent in healthcare. “At CEO and C-suite level I look for authenticity, passion and values. Why is passion so important and perhaps more so in healthcare than in other industries? We need individuals who really want to solve some of the biggest societal problems – working together with end-users to improve global patient health.”